Q-omics provides the consensus-scored TMEM115 profile across patient tissues and cancer cell-line models. TMEM115 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TMEM115 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TMEM115 RNA expression shows 19,039 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, and ACC as cancer lineages where TMEM115 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM115 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM115 survival associations across molecular data types. TMEM115 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM115 RNA expression–survival associations across cancer types. High TMEM115 expression shows unfavorable associations in LIHC, LGG, LAML and ACC, but favorable associations in UVM and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TMEM115 RNA expression.
This table summarizes TMEM115 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM115. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM115 shows lower tumor expression in THCA, LUAD and KICH and higher tumor expression in LIHC, KIRP and STAD. The LIHC box plot shows higher TMEM115 RNA expression in tumor versus normal tissue (log2 FC = +1.156, t-test p < 0.001).
This table shows molecular features associated with TMEM115 in patient tissues and cancer cell lines. In patient samples, TMEM115 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM115 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
